Physicians' perception of guideline-recommended low-density lipoprotein target values: Characteristics of misclassified patients

European Heart Journal

Volumn 31, Issue 10, 2010, Pages 1266-1273

  Sager, Hendrik B ^a   Linsel Nitschke, Patrick ^a   Mayer, Björn ^a   Lieb, Wolfgang ^a   Franzel, Brigitte ^b   Elsasser, Ulrich ^c   Schunkert, Heribert ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b Essex Pharma   (Germany)

^c MedPharmTec   (Germany)

Author keywords

Cardiovascular risk; Hyperlipidaemia; Lipid lowering treatment; Primary prevention; Secondary prevention

Indexed keywords

LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; AWARENESS; CALCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; MALE; PERCEPTION; PHYSICIAN; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROBABILITY; REFERENCE VALUE; SEX DIFFERENCE;

AGED; ATTITUDE OF HEALTH PERSONNEL; ATTITUDE TO HEALTH; CLINICAL COMPETENCE; DIAGNOSTIC ERRORS; FEMALE; GERMANY; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PERCEPTION; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE;

EID: 77952358246     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehq026     Document Type: Article

References (40)

1. Gensini GF, Comeglio M, Colella A. Classical risk factors and emerging elements in the risk profile for coronary artery disease. Eur Heart J 1998;19(Suppl. A): A53-A61.
2. Kannel WB, Larson M. Long-term epidemiologic prediction of coronary disease. The Framingham experience. Cardiology 1993;82:137-152.
3. Keil U. Coronary artery disease: the role of lipids, hypertension and smoking. Basic Res Cardiol 2000;95(Suppl. 1):I52-I58.
4. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-2445.
5. Waters DD, Schwartz GG, Olsson AG, Zeiher A, Oliver MF, Ganz P, Ezekowitz M, Chaitman BR, Leslie SJ, Stern T. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocar-dial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) sub-study. Circulation 2002;106:1690-1695.
6. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361:1149-1158. (Pubitemid 36398384)
7. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504.
8. Colquhoun D, Keech A, Hunt D, Marschner I, Simes J, Glasziou P, White H, Barter P, Tonkin A. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipo-protein cholesterol: results from the LIPID study. Eur Heart J 2004;25:771-777.
9. Goldberg AC, Sapre A, Liu J, Capece R, Mitchel YB. Efficacy and safety of ezeti-mibe coadministered with simvastatin in patients with primary hypercholesterole-mia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2004;79: 620-629.
10. Kjekshus J, Pedersen TR. Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1995;76:64C-68C.
11. Baessler A, Fischer M, Huf V, Mell S, Hengstenberg C, Mayer B, Holmer S, Riegger G, Schunkert H. Failure to achieve recommended LDL cholesterol levels by suboptimal statin therapy relates to elevated cardiac event rates. Int J Cardiol 2005;101:293-298.
12. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK. Intensive lipid lowering with ator-vastatin in patients with stable coronary disease. N Engl J Med 2005;352: 1425-1435.
13. Austin PC, Mamdani MM. Impact of the pravastatin or atorvastatin evaluation and infection therapy\thrombolysis in myocardial infarction 22/Reversal of Atherosclerosis with Aggressive Lipid Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada. Circulation 2005;112:1296-1300.
14. Koren MJ, Hunninghake DB. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am Coll Cardiol 2004;44:1772-1779.
15. Feldman T, Koren M, Insull W Jr, McKenney J, Schrott H, Lewin A, Shah S, Sidisin M, Cho M, Kush D, Mitchel Y. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol 2004;93:1481-1486.
16. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006; 113:2363-2372. (Pubitemid 43947981)
17. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Herrmann-Lingen C, Hoes A, Humphries S, Knapton M, Perk J, Priori SG, Pyorala K, Reiner Z, Ruilope L, Sans-Menendez S, Scholte op Reimer W, Weissberg P, Wood D, Yarnell J, Zamorano JL, Walma E, Fitzgerald T, Cooney MT, Dudina A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Funck-Brentano C, Filippatos G, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Altiner A, Bonora E, Durrington PN, Fagard R, Giampaoli S, Hemingway H, Hakansson J, Kjeldsen SE, Larsen ML, Mancia G, Manolis AJ, Orth-Gomer K, Pedersen T, Rayner M, Ryden L, Sammut M, Schneiderman N, Stalenhoef AF, Tokgozoglu L, Wiklund O, Zampelas A. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007;28:2375-2414.
18. Grundy SM. Approach to lipoprotein management in 2001 National Cholesterol Guidelines. Am J Cardiol 2002;90:11i-21i.
19. Gohlke H, Albus C, Gysan DB, Hahmann HW, Mathes P. Cardiovascular prevention in clinical practice (ESC and German guidelines 2007). Herz 2009;34:4-14.
20. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004;44:720-732.
21. Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
22. Pyorala K, Lehto S, De Bacquer D, De Sutter J, Sans S, Keil U, Wood D, De Backer G. Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EUROASPIRE I AND II surveys. Diabetolo-gia 2004;47:1257-1265.
23. Baessler A, Hengstenberg C, Holmer S, Fischer M, Mayer B, Hubauer U, Klein G, Riegger G, Schunkert H. Long-term effects of in-hospital cardiac rehabilitation on the cardiac risk profile. A case-control study in pairs of siblings with myocardial infarction. Eur Heart J 2001;22:1111-1118. (Pubitemid 32666652)
24. Baessler A, Fischer M, Hengstenberg C, Holmer S, Hubauer U, Huf V, Mell S, Klein G, Riegger G, Schunkert H. Inpatient rehabilitation improves implementation of therapeutic guidelines for secondary prevention in patients with coronary heart disease. Z Kardiol 2001;90:646-654.
25. Bergmann A, Schulze J, Hubner D, Weizel A, Julius U, Kreuzer J. Lipid-lowering therapy and cholesterol levels following acute myocardial infarction: a German study of 5361 patients. Eur J Epidemiol 2003;18:407-411.
26. Fix KN, Oberman A. Barriers to following National Cholesterol Educational Program guidelines. An appraisal of poor physician compliance. Arch Intern Med 1992;152:2385-2387.
27. Mayer B, Linsel-Nitschke P, Lieb W, Franzel B, Elsasser U, Schunkert H. Influence of physicians' knowledge on treatment quality in hypercholesterolaemia\results of the Manage Lipids Study. Clin Res Cardiol 2006;95(Suppl. 5):1338.
28. Gohlke H, Kubler W, Mathes P, Meinertz T, Schuler G, Gysan DB, Sauer G. Recommendations for an extensive risk decrease for patients with coronary disease, vascular diseases and diabetes. Issued by the Executive Committee of the German Society of Cardiology, Heart and Circulation Research, reviewed on behalf of the Clinical Cardiology Commission by the Prevention Project Group. Z Kardiol 2001; 90:148-149.
29. Gohlke H, Kubler W, Mathes P, Meinertz T, Schuler G, Gysan DB, Sauer G. Policy paper on primary prevention of cardiovascular diseases. Current draft of 3/25/2003 issued by the Executive Committee of the German Society of Cardiology, Heart and Circulation Research. Edited by the Prevention Project Group on behalf of the Executive Committee. Z Kardiol 2003;92:522-523.
30. Roncaglioni MC, Avanzini F, Roccatagliata D, Monesi L, Tamayo-Benitez D, Tombesi M, Caimi V, Longoni P, Lauri D, Barlera S, Tognoni G. How general practitioners perceive and grade the cardiovascular risk of their patients. Eur J Cardiovasc Prev Rehabil 2004;11:233-238.
31. Foley KA, Denke MA, Kamal-Bahl S, Simpson R Jr, Berra K, Sajjan S, Alexander CM. The impact of physician attitudes and beliefs on treatment decisions: lipid therapy in high-risk patients. Med Care 2006;44:421-428.
32. Ansell BJ, Fonarow GC, Maki KC, Dicklin MR, Bell M, Davidson MH. Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: results of a national survey. Am Heart J 2006;152: 976-981.
33. Mosca L, Linfante AH, Benjamin EJ, Berra K, Hayes SN, Walsh BW, Fabunmi RP, Kwan J, Mills T, Simpson SL. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation 2005;111:499-510.
34. Daly C, Clemens F, Lopez Sendon JL, Tavazzi L, Boersma E, Danchin N, Delahaye F, Gitt A, Julian D, Mulcahy D, Ruzyllo W, Thygesen K, Verheugt F, Fox KM. Gender differences in the management and clinical outcome of stable angina. Circulation 2006;113:490-498.
35. Banegas JR, Vegazo O, Serrano P, Luengo E, Mantilla T, Fernandez R, Civeira F. The gap between dyslipidemia control perceived by physicians and objective control patterns in Spain. Atherosclerosis 2006;188:420-424.
36. Yan AT, Yan RT, Tan M, Hackam DG, Leblanc KL, Kertland H, Tsang JL, Jaffer S, Kates ML, Leiter LA, Fitchett DH, Langer A, Goodman SG. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med 2006; 119:676-683.
37. Davidson MH, Maki KC, Pearson TA, Pasternak RC, Deedwania PC, McKenney JM, Fonarow GC, Maron DJ, Ansell BJ, Clark LT, Ballantyne CM. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol 2005;96:556-563.
38. Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005; 80:587-595.
39. Amsterdam EA, Laslett L, Diercks D, Kirk JD. Reducing the knowledge-practice gap in the management of patients with cardiovascular disease. Prev Cardiol 2002;5:12-15.
40. Daly C, Clemens F, Lopez-Sendon JL, Tavazzi L, Boersma E, Danchin N, Delahaye F, Gitt A, Julian D, Mulcahy D, Ruzyllo W, Thygesen K, Verheugt F, Fox KM. The impact of guideline compliant medical therapy on clinical outcome in patients with stable angina: findings from the Euro Heart Survey of stable angina. Eur Heart J 2006;27:1298-1304.